Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | $81.16 |
Close | $80.39 |
Volume / Avg. | 625.49K / 1.11M |
Day Range | 79.43 - 82.00 |
52 Wk Range | 45.50 - 84.89 |
Market Cap | $8.49B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 66 |
Short Interest | 3.18% |
Days to Cover | 2.9 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ:ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
There is no analysis for Intra-Cellular Therapies.
Intra-Cellular Therapies has a consensus price target of $88.69.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $80.39 last updated July 26, 2024 at 4:46 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q2 earnings are confirmed for Wednesday, August 7, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.